The risk of developing DKA was almost two times higher in patients with DM2 taking SGLT2 inhibitors than in those taking placebo (2.20, 95% CI 1.25–3.87), but the event rates were low (< 1 per 1000 patient-years) [11]. This evidence concerns the gene SLC5A2 and myotonic dystrophy type 2.